LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Allakos (NASDAQ:ALLK) Inc on Tuesday, setting a price target of $197, which is approximately 136.24% above the...
H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Allakos (NASDAQ:ALLK) Inc on Monday, setting a price target of $230, which is approximately 179.16% above the...
Allakos (ALLK): Q2 GAAP EPS of -$1.07 in-line.Allakos ended the second quarter of 2021 with $559.7 million in cash, cash equivalents and marketable securities.Press Release
Los Angeles, June 08, 2021 (GLOBE NEWSWIRE) -- A Comprehensive Analysis of 18+ Key Companies Strengthening Chronic Spontaneous Urticaria Pipeline | Insights by DelveInsightFor...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 146.06 | 148.82 | 145.76 | -2.73 | -1.83% | 124.93M | NASDAQ | |||
| 2,816.00 | 2,869.00 | 2,809.40 | -56.2 | -1.96% | 2.49M | NASDAQ | |||
| 364.72 | 371.41 | 361.59 | -8.34 | -2.24% | 25.87M | NASDAQ | |||
| 199.75 | 203.27 | 199.45 | -3.85 | -1.89% | 6.34M | NYSE | |||
| 96.76 | 98.38 | 96.37 | -0.56 | -0.58% | 15.28M | NYSE | |||
| 58.18 | 59.11 | 57.03 | -0.21 | -0.36% | 1.47M | NYSE | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 109.62 | 111.11 | 109.18 | +0.06 | +0.05% | 2.83M | NYSE | |||
| 5.48 | 5.58 | 5.43 | -0.100 | -1.79% | 18.39M | NYSE | |||
| 0.4552 | 0.00 | 0.00 | -0.0049 | -1.06% | 2.15M | NYSE | |||
| 43.89 | 44.46 | 43.31 | -0.58 | -1.30% | 54.77M | NYSE | |||
| 18.36 | 18.49 | 18.26 | -0.15 | -0.81% | 20.29M | NYSE | |||
| 12.31 | 12.31 | 11.86 | +0.20 | +1.65% | 7.48M | NYSE | |||
| 53.23 | 53.63 | 53.01 | -0.60 | -1.11% | 2.09M | NYSE | |||
| 19.36 | 19.46 | 19.07 | -0.21 | -1.07% | 6.10M | NYSE |
Allakos Inc. operates as a clinical stage biopharmaceutical company. The company’s lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; and a Phase II/III study for the treatment of eosinophilic esophagitis. The is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, severe allergic conjunctivitis, chronic urticaria, and indolent systemic mastocytosis. Allakos Inc. was incorporated in 2012 and is headquartered in Redwood City, California.